{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:36:24Z","timestamp":1792773384092,"version":"4.5.0"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Antiseizure medications (ASMs) are often coprescribed with direct oral anticoagulants (DOACs). The pharmacokinetic (PK) interactions between ASMs and DOACs may result in altered exposure to anticoagulants, potentially increasing the risk of thromboembolic events or bleeding. This review summarizes the clinical evidence on drug\u2013drug interactions between ASMs and DOACs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In accordance with PRISMA-ScR guidelines, a systematic literature search was conducted in PubMed (up to November 2025). All clinical reports and observational datasets reporting the concomitant use of at least 1 ASM and DOAC were included. ASM\u2013DOAC combinations, PK findings, and reported clinical outcomes are presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirty studies were included. Most reports involved enzyme-inducing ASMs (carbamazepine, phenobarbital, primidone, and oxcarbazepine), which were consistently associated with subtherapeutic DOAC plasma concentrations and severe clinical failures. Doubling the DOAC dose did not prevent these events in several cases. Rivaroxaban and apixaban were the most frequently described DOACs, whereas clinical data for edoxaban were limited. Evidence of non\u2013enzyme-inducing ASMs, such as levetiracetam and valproic acid, was limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although enzyme-inducing ASMs compromised DOAC efficacy, the available clinical evidence was fragmented and prone to publication bias. The observed variability in interactions involving noninducing ASMs such as levetiracetam underlines the clinical complexity that may exceed theoretical PK predictions. Given the unpredictability of these interactions and the failure of empirical dose adjustments, a standardized approach for therapeutic drug monitoring and prospective, comparative trials are essential to guide personalized therapy in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001528","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:01:20Z","timestamp":1792767680000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Interactions Between Antiseizure Medications and Direct Oral Anticoagulants: A Scoping Review on Therapeutic Failures and Knowledge Gaps"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7637-2404","authenticated-orcid":false,"given":"Chiara","family":"Cancellerini","sequence":"first","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Esposto","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Full member of the European Reference Network EpiCARE, Bologna, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Caravelli","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Full member of the European Reference Network EpiCARE, Bologna, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Vignatelli","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Full member of the European Reference Network EpiCARE, Bologna, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pasini","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Full member of the European Reference Network EpiCARE, Bologna, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zini","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Neurologia e Rete Stroke Metropolitana, Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mostacci","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Full member of the European Reference Network EpiCARE, Bologna, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Licchetta","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Full member of the European Reference Network EpiCARE, Bologna, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bisulli","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy;"},{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Full member of the European Reference Network EpiCARE, Bologna, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"R1-20261023","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2176\/nmc.ra.2015-0344","article-title":"The new antiepileptic drugs: their neuropharmacology and clinical indications","volume":"56","author":"Hanaya","year":"2016","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"R2-20261023","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS drugs"},{"key":"R3-20261023","doi-asserted-by":"crossref","first-page":"991244","DOI":"10.3389\/fphar.2022.991244","article-title":"Epilepsy treatment in neuro-oncology: a rationale for drug choice in common clinical scenarios","volume":"13","author":"S\u00e1nchez-Villalobos","year":"2022","journal-title":"Front Pharmacol."},{"key":"R4-20261023","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40266-021-00837-7","article-title":"Seizures and epilepsy after stroke: epidemiology, biomarkers and management","volume":"38","author":"Galovic","year":"2021","journal-title":"Drugs Aging"},{"key":"R5-20261023","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.13813","article-title":"Stroke-related epilepsy","volume":"26","author":"Feyissa","year":"2019","journal-title":"Eur J Neurol."},{"key":"R6-20261023","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/2042098617719815","article-title":"Potential drug\u2013drug interactions with direct oral anticoagulants in elderly hospitalized patients","volume":"8","author":"Forbes","year":"2017","journal-title":"Ther Adv Drug Saf."},{"key":"R7-20261023","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non\u2013vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"R8-20261023","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s11864-023-01116-w","article-title":"Management of thromboembolic disease in patients with primary and metastatic brain tumors","volume":"24","author":"Woods","year":"2023","journal-title":"Curr Treat Options Oncol."},{"key":"R9-20261023","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)\u2014part 1: pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"R10-20261023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40263-023-00990-0","article-title":"Interactions between direct oral anticoagulants (DOACs) and antiseizure medications: potential implications on DOAC treatment","volume":"37","author":"Goldstein","year":"2023","journal-title":"CNS Drugs"},{"key":"R11-20261023","doi-asserted-by":"crossref","first-page":"106304","DOI":"10.1016\/j.eplepsyres.2020.106304","article-title":"The interactions between anticonvulsants and non-vitamin K antagonist oral anticoagulant agents: a systematic review","volume":"162","author":"Taha","year":"2020","journal-title":"Epilepsy Res."},{"key":"R12-20261023","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic Disord"},{"key":"R13-20261023","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/eurheartj\/ehz091","article-title":"Combination of non-vitamin K antagonist oral anticoagulants and antiepileptic drugs","volume":"40","author":"Kurt","year":"2019","journal-title":"Eur Heart J."},{"key":"R14-20261023","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fneur.2018.01067","article-title":"Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs","volume":"9","author":"Galgani","year":"2018","journal-title":"Front Neurol."},{"key":"R15-20261023","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2004.04.011","article-title":"Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans","volume":"76","author":"Giessmann","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"R16-20261023","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1021\/acs.molpharmaceut.6b00770","article-title":"P-gp protein expression and transport activity in rodent seizure models and human epilepsy","volume":"14","author":"Hartz","year":"2017","journal-title":"Mol Pharm."},{"key":"R17-20261023","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","article-title":"The transport of antiepileptic drugs by P-glycoprotein","volume":"64","author":"Zhang","year":"2012","journal-title":"Adv Drug Deliv Rev."},{"key":"R18-20261023","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.seizure.2020.05.024","article-title":"Clinically relevant interaction of rivaroxaban and valproic acid\u2014a case report","volume":"80","author":"Langenbruch","year":"2020","journal-title":"Seizure"},{"key":"R19-20261023","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)","volume":"52","author":"Wen","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"R20-20261023","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.0013-9580.2003.06203.x","article-title":"Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate","volume":"44","author":"Nallani","year":"2003","journal-title":"Epilepsia"},{"key":"R21-20261023","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1528-1167.2007.00924.x","article-title":"A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on Cyp3a4","volume":"48","author":"Andreasen","year":"2007","journal-title":"Epilepsia"},{"key":"R22-20261023","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/00498254.2015.1118774","article-title":"Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells","volume":"46","author":"Sugiyama","year":"2016","journal-title":"Xenobiotica"},{"key":"R23-20261023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1535-7511.2009.01336.x","article-title":"Rufinamide: a novel broad-spectrum antiepileptic drug","volume":"10","author":"Wheless","year":"2010","journal-title":"Epilepsy Curr."},{"key":"R24-20261023","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bcp.12951","article-title":"Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials","volume":"82","author":"Majid","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R25-20261023","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40261-020-00982-8","article-title":"Concomitant use of direct oral anticoagulants and antiepileptic drugs: a prospective cohort study in patients with atrial fibrillation","volume":"41","author":"Giustozzi","year":"2021","journal-title":"Clin Drug Investig."},{"key":"R26-20261023","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40262-015-0276-0","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lacosamide","volume":"54","author":"Cawello","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"R28-20261023","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10072-023-06992-6","article-title":"Pilot study on the probability of drug-drug interactions among direct oral anticoagulants (DOACs) and antiseizure medications (ASMs): a clinical perspective","volume":"45","author":"Ranzato","year":"2024","journal-title":"Neurol Sci."},{"key":"R29-20261023","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug\u2013drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"R30-20261023","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New Engl J Med."},{"key":"R31-20261023","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J."},{"key":"R33-20261023","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2174\/1389200218666170427113504","article-title":"Dabigatran\u2014metabolism, pharmacologic properties and drug interactions","volume":"18","author":"Antonijevic","year":"2017","journal-title":"Curr Drug Metab."},{"key":"R34-20261023","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","article-title":"Rivaroxaban: a new oral factor xa inhibitor","volume":"30","author":"Perzborn","year":"2010","journal-title":"Arteriosclerosis Thromb Vasc Biol."},{"key":"R35-20261023","doi-asserted-by":"crossref","DOI":"10.2165\/00003495-200868120-00007","article-title":"ADIS DRUG PROFILE dabigatran etexilate","author":"Sanford","year":"2008","journal-title":"Drugs"},{"key":"R36-20261023","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/1389200218666170424151551","article-title":"Apixaban\u2014Metabolism, pharmacologic properties and drug interactions","volume":"18","author":"Kubisz","year":"2017","journal-title":"Curr Drug Metab."},{"key":"R37-20261023","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2146\/ajhp150821","article-title":"Edoxaban: a direct oral anticoagulant","volume":"74","author":"Poulakos","year":"2017","journal-title":"Am J Health Syst Pharm."},{"key":"R38-20261023","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R39-20261023","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.medcli.2017.11.042","article-title":"Direct oral anticoagulants: an update","volume":"151","author":"Franco Moreno","year":"2018","journal-title":"Med Clin (Barc)"},{"key":"R40-20261023","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of Edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"R41-20261023","first-page":"S24","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can J Cardiol."},{"key":"R42-20261023","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharmacol Res."},{"key":"R43-20261023","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2174\/1389200218666170518165443","article-title":"Rivaroxaban\u2014Metabolism, pharmacologic properties and drug interactions","volume":"18","author":"Kvasnicka","year":"2017","journal-title":"Curr Drug Metab."},{"key":"R44-20261023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2025.2500722","article-title":"Risk of thromboembolic events in patients co-treated with factor Xa-inhibiting direct oral anticoagulants and anti-seizure medications: insights from pharmacovigilance data","volume":"1","author":"Ding","year":"2025","journal-title":"Expert Opin Drug Saf."},{"key":"R45-20261023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MBC.0000000000001342","article-title":"Impact of cytochrome P-450 3A4 enzyme\/P-glycoprotein inducing antiseizure medications on direct oral anticoagulant therapy","volume":"36","author":"McNary","year":"2025","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R46-20261023","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"R47-20261023","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1389200221666200620210522","article-title":"FDA Drug\u2013drug interaction guidance: a comparison analysis and action plan by pharmaceutical industrial scientists","volume":"21","author":"Sudsakorn","year":"2020","journal-title":"Curr Drug Metab."},{"key":"R48-20261023","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cpt.2369","article-title":"Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study","volume":"110","author":"Gronich","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R49-20261023","doi-asserted-by":"crossref","first-page":"100137","DOI":"10.1016\/j.rpth.2023.100137","article-title":"Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: a systematic review","volume":"7","author":"Candeloro","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"key":"R50-20261023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R51-20261023","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med."},{"key":"R52-20261023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev."},{"key":"R53-20261023","doi-asserted-by":"crossref","first-page":"1542063","DOI":"10.3389\/fphar.2025.1542063","article-title":"Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers","volume":"16","author":"Lenard","year":"2025","journal-title":"Front Pharmacol."},{"key":"R54-20261023","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/00185787221150928","article-title":"Managing the drug-drug interaction with apixaban and primidone: a case report","volume":"58","author":"Manis","year":"2023","journal-title":"Hosp Pharm."},{"key":"R55-20261023","first-page":"e83268","article-title":"Stroke and thrombotic events associated with concomitant use of oral anticoagulants and antiepileptic drugs in the United States and Japan","volume":"17","author":"Sunaga","year":"2025","journal-title":"Cureus"},{"key":"R56-20261023","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s40263-023-01052-1","article-title":"Levetiracetam interaction with direct oral anticoagulants: a pharmacovigilance study","volume":"37","author":"Abou Kaoud","year":"2023","journal-title":"CNS Drugs"},{"key":"R57-20261023","doi-asserted-by":"crossref","first-page":"9257","DOI":"10.1038\/s41598-023-33876-8","article-title":"The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam","volume":"13","author":"Mavri","year":"2023","journal-title":"Sci Rep."},{"key":"R58-20261023","article-title":"[Pulmonary embolism due to interaction between rivaroxaban and carbamazepine]","author":"Risselada","year":"2013","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R59-20261023","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.hrtlng.2014.03.004","article-title":"Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state","volume":"43","author":"St\u00f6llberger","year":"2014","journal-title":"Heart Lung J Crit Care"},{"key":"R60-20261023","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4081\/cp.2015.788","article-title":"Left atrial appendage thrombosis during therapy with rivaroxaban in elective cardioversion for permanent atrial fibrillation","volume":"5","author":"Serra","year":"2015","journal-title":"Clin Pract."},{"key":"R61-20261023","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1002\/phar.1698","article-title":"Reduced anticoagulant effect of Dabigatran in a patient receiving concomitant phenytoin","volume":"36","author":"Wiggins","year":"2016","journal-title":"Pharmacotherapy"},{"key":"R62-20261023","first-page":"4760612","article-title":"Decreased rivaroxaban levels in a patient with cerebral vein thrombosis receiving phenytoin","volume":"2017","author":"Becerra","year":"2017","journal-title":"Case Rep Hematol."},{"key":"R63-20261023","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4212\/cjhp.v70i6.1714","article-title":"Apixaban concentration with and without coadministration of carbamazepine: a case with no apparent interaction","volume":"70","author":"Evanger","year":"2017","journal-title":"Can J Hosp Pharm."},{"key":"R64-20261023","first-page":"554.e13","article-title":"Development of left atrial thrombus after coadministration of dabigatran etexilate and phenytoin","volume":"33","author":"Hager","year":"2017","journal-title":"Can J Cardiol."},{"key":"R65-20261023","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pjnns.2017.01.010","article-title":"Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy","volume":"51","author":"St\u00f6llberger","year":"2017","journal-title":"Neurol Neurochir Pol."},{"key":"R66-20261023","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7861\/clinmedicine.18-1-103","article-title":"Lesson of the month 2: pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine","volume":"18","author":"Burden","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"R67-20261023","first-page":"1534.e1","article-title":"Managing direct oral anticoagulants in patients with antiepileptic medication","volume":"34","author":"Dagan","year":"2018","journal-title":"Can J Cardiol."},{"key":"R68-20261023","first-page":"e93905","article-title":"Tailoring anticoagulant therapy: managing interactions between carbamazepine and direct oral anticoagulants (DOACs)","volume":"17","author":"Mohammed","year":"2025","journal-title":"Cureus"},{"key":"R69-20261023","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11239-019-01866-1","article-title":"Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy","volume":"48","author":"Di Gennaro","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"R70-20261023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7326\/L19-0712","article-title":"Rivaroxaban plasma levels and levetiracetam: a case report","volume":"173","author":"Paciullo","year":"2020","journal-title":"Ann Intern Med."},{"key":"R71-20261023","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cjco.2020.04.009","article-title":"Carbamazepine induction impacting apixaban concentrations: a case report","volume":"2","author":"Bungard","year":"2020","journal-title":"CJC Open"},{"key":"R72-20261023","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/1060028021990374","article-title":"Rivaroxaban failure in a patient taking oxcarbazepine","volume":"55","author":"Robinson","year":"2021","journal-title":"Ann Pharmacother."},{"key":"R73-20261023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cjco.2021.12.012","article-title":"The problem with predictions: a cautionary tale of empirically adjusting apixaban dosing with carbamazepine","volume":"4","author":"Chadha","year":"2022","journal-title":"CJC Open"},{"key":"R74-20261023","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/ajhp\/zxac054","article-title":"Acute elevation of liver function test values following concomitant administration of dabigatran and primidone","volume":"79","author":"Caviness","year":"2022","journal-title":"Am J Health Syst Pharm."},{"key":"R75-20261023","doi-asserted-by":"crossref","first-page":"ytad006","DOI":"10.1093\/ehjcr\/ytad006","article-title":"Minimizing drug-drug interactions between dabigatran and levetiracetam through clinical management: a case report","volume":"7","author":"Menichelli","year":"2023","journal-title":"Eur Heart J Case Rep."},{"key":"R76-20261023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/1060028018759938","article-title":"Management of phenobarbital and apixaban interaction in recurrent cardioembolic stroke","volume":"52","author":"King","year":"2018","journal-title":"Ann Pharmacother."},{"key":"R77-20261023","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.clinthera.2024.06.002","article-title":"Direct oral anticoagulants and concomitant anti-seizure medications: a retrospective, case\u2013control study in a real-world setting","volume":"46","author":"Rota","year":"2024","journal-title":"Clin Ther."},{"key":"R78-20261023","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/epi.17822","article-title":"The extent of cytochrome P450 3A induction by antiseizure medications: a systematic review and network meta-analysis","volume":"65","author":"Cohen","year":"2024","journal-title":"Epilepsia"},{"key":"R79-20261023","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jpba.2017.10.011","article-title":"Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy","volume":"148","author":"Foerster","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"R80-20261023","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjh.13810","article-title":"Laboratory measurement of the direct oral anticoagulants","volume":"172","author":"Dale","year":"2016","journal-title":"Br J Haematol."},{"key":"R81-20261023","doi-asserted-by":"crossref","first-page":"e2300084","DOI":"10.1002\/jssc.202300084","article-title":"A high-throughput liquid chromatography-tandem mass spectrometry method for simultaneous determination of direct oral anticoagulants in human plasma","volume":"46","author":"\u017didekov\u00e1","year":"2023","journal-title":"J Sep Sci."},{"key":"R82-20261023","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.aca.2019.03.061","article-title":"Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: a critical review","volume":"1076","author":"Gouveia","year":"2019","journal-title":"Anal Chim Acta"},{"key":"R83-20261023","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.amjmed.2016.06.017","article-title":"Measurement of dabigatran drug levels to manage patients taking interacting drugs: a case report","volume":"129","author":"Laureano","year":"2016","journal-title":"Am J Med."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:01:30Z","timestamp":1792767690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":81,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001528","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"2026-04-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}